Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer

Cancer Immunology, Immunotherapy

Volumn 64, Issue 6, 2015, Pages 689-696

  Smith, Sean G ^a   Koppolu, Bhanu prasanth ^a   Ravindranathan, Sruthi ^a   Kurtz, Samantha L ^a   Yang, Lirong ^a   Katz, Matthew D ^b   Zaharoff, David A ^a,b  

^a University of Arkansas   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bladder cancer; Chitosan; Interleukin 12; Intravesical immunotherapy

Indexed keywords

CHITOSAN DERIVATIVE; CHITOSAN GLUTAMATE; INTERLEUKIN 12; UNCLASSIFIED DRUG; CHITOSAN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; LONG TERM SURVIVAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; C3H MOUSE; C57BL MOUSE; DOSE RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZATION; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANIMALS; CELL LINE, TUMOR; CHITOSAN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-12; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; RANDOM ALLOCATION; URINARY BLADDER NEOPLASMS;

EID: 84930417773     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1672-x     Document Type: Article

References (30)

1. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol 42(Suppl 218):12–20
2. Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289–293
3. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239–249
4. Morales A, Eidinger D, Bruce A (1976) Intracavitary Bacillus Calmette–Guerin in the treatment of superficial bladder tumors. J Urol 116:180–183
5. Alexandroff AB, Jackson AM, O’Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689–1694
6. Anastasiadis A, de Reijke TM (2012) Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 4:13–32
7. Lamm DL, Van der Meijden P, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne F (1992) Incidence and treatment of complications of bacillus Calmette–Guerin intravesical therapy in superficial bladder cancer. J Urol 147:596–600
8. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ (1999) 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette–Guerin in patients with superficial bladder carcinoma. J Urol 161:1124–1127
9. Askeland EJ, Newton MR, O’Donnell MA, Luo Y (2012) Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012:181987
10. Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ Jr, Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW (2009) Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res 69:6192–6199
11. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146
12. Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155–168
13. Yang L, Zaharoff DA (2013) Role of chitosan co-formulation in enhancing interleukin-12 delivery and antitumor activity. Biomaterials 34:3828–3836
14. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7(11):1705–1721
15. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677–4685
16. McNeela EA, Jabbal-Gill I, Illum L, Pizza M, Rappuoli R, Podda A, Lewis DJ, Mills KH (2004) Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22:909–914
17. Wedmore I, McManus JG, Pusateri AE, Holcomb JB (2006) A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 60(3):655–658
18. Illum L (1998) Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326–1331
19. Arai K, Kinumaki T, Fujita T (1968) Toxicity of chitosan. Bull Tokai Region Fish Res Lab 56:89–94
20. O’Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK (2004) Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol 171:1330–1335
21. Horinaga M, Harsch KM, Fukuyama R, Heston W, Larchian W (2005) Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 66:461–466
22. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL (1997) Effects of single-dose interleukin-12 exposure on interleukin-12—associated toxicity and interferon-γ production. Blood 90:2541–2548
23. Hunter SE, Waldburger KE, Thibodeaux DK, Schaub RG, Goldman SJ, Leonard JP (1997) Immunoregulation by interleukin-12 in MB49. 1 tumor-bearing mice: cellular and cytokine-mediated effector mechanisms. Eur J Immunol 27:3438–3446
24. Herr HW, Dotan Z, Donat SM, Bajorin DF (2007) Defining optimal therapy for muscle invasive bladder cancer. J Urol 177:437–443
25. Summerhayes I, Franks L (1979) Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 62:1017–1023
26. Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmstrom PU, Totterman TH (2005) Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim 39:384–393. doi:10.1258/002367705774286475
27. Halak BK, Maguire HC, Lattime EC (1999) Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59:911–917
28. Dekernion JB, Soloway MS, Persky L (1974) Chemotherapy of experimental transitional-cell carcinoma. Urology 4:63–68
29. Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, Litwin MS (2011) Compliance with guidelines for patients with bladder cancer. Cancer 117:5392–5401
30. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95:588–597